SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
371 27 0 IMMU
Emcee:  Josh C. Pleasure, M.D. Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
346Just a brief visit..this was in JCO today..I don't follow nor know this compzeta1961-8/21/2006
345Nigel: Glad to see somebody is on this board, although this is the first time Ierickerickson-5/22/2006
344Immunomedics and UCB Announce Worldwide Development Collaboration and License Agnigel bates-5/10/2006
343Message 21724233DewDiligence_on_SI-9/21/2005
342To all: This was posted on the Lupus of America website. We are getting some atmhubs-1/18/2005
341I don't believe it was, Zevalin and BEXXAR are both there for that as the raidahoranch1-1/14/2005
340Banker, IMMU does not have the resources to complete the pivotal phase lll trialidahoranch1-1/14/2005
339Another question for the board -- was Emab ever evaluated as a salvage therapy fI_Banker-1/13/2005
338Does IMMU have the resources to undertake a Phase 3 without a partner? How longI_Banker-1/13/2005
337Banker, it was not a double blind nor a head to head. They simply infused CD22 aidahoranch1-1/9/2005
336Idaho, are you saying that the failed Amgen trial was not a double blind study cI_Banker-1/8/2005
335Banker, he certainly has the right to his viewpoint. No doubt his investment dididahoranch1-1/8/2005
334Kitty2, I don't know the answers to those questions, but as to the last one,idahoranch1-1/8/2005
333I was talking to an oncologist who was a former investor in IMMU and he told me I_Banker-1/8/2005
332idaho1 do you know what % of companies with fast track approval do not ultimatelkitty2-1/8/2005
331thank you erick for your thorough replykitty2-1/6/2005
330So, like, how should Idaho know? He's not a company officer. Sorry, couldn&#erickerickson-1/6/2005
329idahoranch1 how will immu conduct a phase 111 on lupus w/o a partner?kitty2-1/6/2005
328Sjogrens is an autoimmune disease that stops glands from secreting fluids, so thidahoranch1-1/5/2005
327Idaho, thanks for the explanation -- though I am unfamiliar with Sjogrens. On aI_Banker-1/5/2005
326It is estimated that 1.5 million people suffer from lupus in the US, and 20% of idahoranch1-1/5/2005
325Anyone have an idea on what the market size is for a lupus treatment?I_Banker-1/5/2005
324Well, I'm not entirely familiar with the details, but here's what Fast Terickerickson-1/5/2005
323A good friend would ask me if I understood what I know. Here is a good example suite2320-1/5/2005
322This sounds like promising news for IMMU. I have been waiting to buy shares, buI_Banker-1/5/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News